Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.58 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.39 |
| ▸ | PPARG | P37231 | 6/20 | 0.39 |
| ▸ | PPARD | Q03181 | 6/20 | 0.39 |
| ▸ | PPARA | Q07869 | 6/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27537263 | 0.98 | TSHR (0.56) | TSHRSLC22A6LMNANFKB1PMP22 | |
| SCHEMBL1403596 | 0.95 | TSHR (0.52) | TSHRSLC22A6LMNANFKB1PMP22 | |
| SCHEMBL2182221 | 0.93 | TSHR (0.52) | TSHRSLC22A6LMNANFKB1PMP22 | |
| SCHEMBL16342359 | 0.93 | TSHR (0.52) | TSHRSLC22A6LMNANFKB1PMP22 | |
| SCHEMBL2037115 | 0.93 | TSHR (0.52) | TSHRSLC22A6LMNANFKB1PMP22 | |
| SCHEMBL25176741 | 0.93 | TSHR (0.52) | TSHRSLC22A6LMNANFKB1PMP22 | |
| SCHEMBL16323109 | 0.93 | TSHR (0.52) | TSHRSLC22A6LMNANFKB1PMP22 | |
| SCHEMBL414546 | 0.93 | TSHR (0.52) | TSHRSLC22A6LMNANFKB1PMP22 | |
| SCHEMBL20897215 | 0.93 | TSHR (0.52) | TSHRSLC22A6LMNANFKB1PMP22 | |
| SCHEMBL557403 | 0.93 | TSHR (0.52) | TSHRSLC22A6LMNANFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367332-A1 | PSMA-TARGETED RADIOACTIVE METAL COMPLEX CONTAINING NITROAROMATIC HETEROCYCLIC GROUP AND PREPARATION METHOD | UNIV BEIJING NORMAL (CN) | 2025-12-04 | — | — | US | claimed |
| CN-119638781-B | Synthesis method of antibody-coupled drug linker | 瑞博(苏州)制药有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-119638781-A | Synthesis method of antibody-coupled drug linker | 瑞博(苏州)制药有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-119604492-A | Radiolabeled FAPI complex and preparation method and application thereof | 北京师范大学 | 2025-03-11 | — | — | CN | claimed |
| WO-2023231452-A1 | PSMA-TARGETING RADIOACTIVE METAL COMPLEX CONTAINING NITRO AROMATIC HETEROCYCLIC GROUP AND PREPARATION THEREOF | 北京师范大学 | 2023-12-07 | — | — | WO | claimed |
| CN-116507630-A | PSMA targeted radioactive metal complex containing nitro aromatic heterocyclic group and preparation thereof | 北京师范大学 | 2023-07-28 | — | — | CN | claimed |
| US-6004823-A | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-21 | — | — | US | claimed |
| EP-4746849-A1 | PHARMACEUTICAL COMPOSITIONS OF INSULIN DERIVATIVES | Novo Nordisk A/S (DK) | 2026-05-27 | — | — | EP | disclosed |
| EP-4368686-B1 | LUBRICITY IMPROVER COMPOSITION FOR FUEL OIL AND USE THEREOF | CHINA PETROLEUM & CHEM CORP (CN) | 2026-05-27 | — | — | EP | disclosed |
| CN-122071478-A | Compound for targeted degradation of GLI1 protein and medicinal application thereof | 苏州大学 | 2026-05-22 | — | — | CN | disclosed |
| CN-122055379-A | Compounds containing one or more diboronate esters and related insulin analogues | 普罗托莫科技公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026098519-A1 | RADIOLIGAND COMPOUNDS AND USES THEREOF | Chengdu New Radiomedicine Technology Co., Ltd. (CN) | 2026-05-15 | — | — | WO | disclosed |
| CN-120590466-B | Compound of targeted fibroblast activation protein and application thereof | 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) | 2026-05-12 | — | — | CN | disclosed |
| US-4464521-A | EPOXIDIZED FULVENES AS BINDER FOR AGGREGATE; FOUNDRY BINDERS | ASHLAND OIL, INC. (US) | 1984-08-07 | — | — | US | disclosed |
| US-4390675-A | EPOXYFULVENE, ACID CATALYST | ASHLAND OIL, INC. (US) | 1983-06-28 | — | — | US | disclosed |
| US-4349552-A | TREATMENT OF CANCER | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1982-09-14 | — | — | US | disclosed |
| EP-0010941-B1 | 5-FLUOROURACIL DERIVATIVES, PREPARATION THEREOF AND THEIR PHARMACEUTICAL COMPOSITIONS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-05-12 | — | — | EP | disclosed |
| US-4220578-A | Method, resin and catalyst for increasing the tensile strength and core hardness of a sand mold or core | CL INDUSTRIES INC. (US) | 1980-09-02 | — | — | US | disclosed |
| US-4215012-A | SULFUR-FREE; DIALKYL ESTER COMPOUND AND A LEWIS ACID, POLYMERIZATION CATALYST | C L INDUSTRIES, INC. (US) | 1980-07-29 | — | — | US | disclosed |
| EP-0010941-A1 | 5-Fluorouracil derivatives, preparation thereof and their pharmaceutical compositions | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367332-A1 | PSMA-TARGETED RADIOACTIVE METAL COMPLEX CONTAINING NITROAROMATIC HETEROCYCLIC GROUP AND PREPARATION METHOD | PSMA1, PSMA2, PSMA7 | TSHR 2373/4885SLC22A6 779/4885LMNA 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.